Antimicrobial resistance interventions in Latin America and the Caribbean: a scoping review of reported interventions between 2018-2024.

Publisher: BioMed Central Country of Publication: England NLM ID: 101585411 Publication Model: Electronic Cited Medium: Internet ISSN: 2047-2994 (Electronic) Linking ISSN: 20472994 NLM ISO Abbreviation: Antimicrob Resist Infect Control Subsets: MEDLINE

Original Publication: London : BioMed Central

Anti-Bacterial Agents*/pharmacology ; Anti-Bacterial Agents*/therapeutic use ; Antimicrobial Stewardship* ; Drug Resistance, Bacterial*; Latin America ; Caribbean Region ; Humans ; Animals

Background: Antimicrobial resistance (AMR) is a critical global health challenge, linked to 4·71 million deaths in 2021 and affecting human health, animals, food, plants, and the environment. This scoping review aims to map out published interventions addressing AMR in the Latin America and Caribbean (LAC) region.
Methods: We searched PubMed, Web of Science, LILACS, and grey literature for articles reporting the implementation of AMR programs, interventions, or policies aimed at tackling AMR published between January 2018 and December 2024.
Results: A total of 82 studies were included, comprising 64 peer-reviewed articles and 18 from grey literature. The majority (n = 75) focused on human health, while a smaller subset (n = 7) addressed animal health. Geographically, most studies were conducted in Brazil (n = 32) and Colombia (n = 22) with only one study in the Caribbean. Antimicrobial stewardship interventions were the primary focus in 50 studies. Only 53 out of 74 studies included an evaluation of the intervention.
Conclusion: Significant gaps remain in AMR research in LAC, particularly in animal and environmental health. Rigorous intervention evaluations are needed to generate high-quality evidence for policy and practice. Increased funding for intervention and implementation research across all sectors is crucial to tackling AMR regionally and globally.
(© 2025. The Author(s).)

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare that this study was funded by the International Centre for Antimicrobial Resistance Solutions (ICARS). While the funding body was involved in the study's conception, interpretation and reviewed the manuscript, it had no role in data collection, or analysis. No additional competing interests are declared.

Lancet. 2022 Feb 12;399(10325):629-655. (PMID: 35065702)
Front Antibiot. 2023 Aug 31;2:1233698. (PMID: 39816662)
Ther Adv Infect Dis. 2025 May 23;12:20499361251340144. (PMID: 40416942)
PLoS One. 2021 Apr 1;16(4):e0249475. (PMID: 33793627)
Ann Intern Med. 2018 Oct 2;169(7):467-473. (PMID: 30178033)
Ann N Y Acad Sci. 2019 Apr;1441(1):17-30. (PMID: 30924539)
Clin Infect Dis. 2021 Dec 1;73(Suppl_4):S283-S289. (PMID: 34850831)
Rev Saude Publica. 2019 Aug 19;53:68. (PMID: 31432930)
Int J Environ Res Public Health. 2021 Sep 18;18(18):. (PMID: 34574760)
Rev Chilena Infectol. 2020 Feb;37(1):9-18. (PMID: 32730394)
Antimicrob Steward Healthc Epidemiol. 2023 Dec 05;3(1):e217. (PMID: 38156226)
Braz J Infect Dis. 2021 Mar-Apr;25(2):101540. (PMID: 33592171)
Open Forum Infect Dis. 2024 Jul 12;11(8):ofae402. (PMID: 39091641)
Infect Prev Pract. 2022 Jan 12;4(1):100201. (PMID: 35141515)
Rev Argent Microbiol. 2022 Apr-Jun;54(2):134-142. (PMID: 34088536)
Antibiotics (Basel). 2023 May 07;12(5):. (PMID: 37237770)
Antibiotics (Basel). 2023 Oct 28;12(11):. (PMID: 37998774)
Infect Prev Pract. 2024 Nov 08;6(4):100419. (PMID: 39691838)
BMC Infect Dis. 2023 Jul 11;23(1):463. (PMID: 37434158)
Antibiotics (Basel). 2022 Aug 25;11(9):. (PMID: 36139929)
BMC Infect Dis. 2022 May 2;22(1):420. (PMID: 35501756)
Int J Infect Control. 2020 Jul 23;16(3):1-6. (PMID: 34135996)
S Afr Med J. 2015 Apr 06;105(5):325. (PMID: 26242647)
Front Public Health. 2021 Jan 14;8:575536. (PMID: 33520909)
Rev Chilena Infectol. 2019 Jun;36(3):253-264. (PMID: 31859743)
Rev Panam Salud Publica. 2023 Apr 28;47:e64. (PMID: 37123640)
Rev Med Chil. 2018 Sep;146(9):968-977. (PMID: 30725016)
J Glob Antimicrob Resist. 2022 Jun;29:462-467. (PMID: 34788689)
PLoS One. 2020 Jan 27;15(1):e0227947. (PMID: 31986167)
BMC Infect Dis. 2023 Sep 11;23(1):593. (PMID: 37697310)
Med Humanit. 2022 Dec;48(4):e16. (PMID: 35321873)
Rev Panam Salud Publica. 2023 Jul 24;47:e106. (PMID: 37489236)
Emerg Infect Dis. 2022 Jan;28(1):180-187. (PMID: 34932455)
BMC Infect Dis. 2023 Jan 11;23(1):21. (PMID: 36631755)
Am J Infect Control. 2018 Apr;46(4):387-392. (PMID: 29217187)
BMC Pharmacol Toxicol. 2024 Jan 25;25(1):11. (PMID: 38273410)
Vaccine. 2021 May 27;39(23):3207-3215. (PMID: 33707062)
Rev Chilena Infectol. 2022 Feb;39(1):7-13. (PMID: 35735274)
JAC Antimicrob Resist. 2023 Apr 28;5(2):dlad050. (PMID: 37124073)
Rev Panam Salud Publica. 2020 Sep 23;44:e45. (PMID: 32973898)
Crit Care. 2021 Jul 26;25(1):261. (PMID: 34311760)
J Infect Dev Ctries. 2020 Jun 30;14(6):664-668. (PMID: 32683359)
Microbiol Spectr. 2018 Mar;6(2):. (PMID: 29600770)
J Med Microbiol. 2018 Jun;67(6):750-756. (PMID: 29717974)
BMC Med Educ. 2019 Jun 7;19(1):191. (PMID: 31174524)
Crit Care. 2020 Jun 1;24(1):281. (PMID: 32487263)
Rev Peru Med Exp Salud Publica. 2018 Jan-Mar;35(1):103-109. (PMID: 29924255)
J Crit Care. 2024 Aug;82:154783. (PMID: 38507842)
Rev Chilena Infectol. 2019 Oct;36(5):565-575. (PMID: 31859797)
PLoS One. 2021 Nov 10;16(11):e0259632. (PMID: 34758027)
Infect Control Hosp Epidemiol. 2022 Feb;43(2):181-190. (PMID: 33829982)
Int J Environ Res Public Health. 2022 Apr 14;19(8):. (PMID: 35457602)
Am J Infect Control. 2022 Jan;50(1):92-98. (PMID: 34425180)
PLoS One. 2022 Jan 28;17(1):e0262731. (PMID: 35089952)
Rev Panam Salud Publica. 2020 Sep 23;44:e68. (PMID: 32973908)
Braz J Infect Dis. 2020 May - Jun;24(3):221-230. (PMID: 32504551)
Syst Rev. 2016 Dec 5;5(1):210. (PMID: 27919275)
J Med Microbiol. 2018 Dec;67(12):1761-1771. (PMID: 30372411)
Rev Chilena Infectol. 2020 Aug;37(4):343-348. (PMID: 33399653)
J Telemed Telecare. 2019 Jun;25(5):294-300. (PMID: 29720043)
Farm Hosp. 2021 Feb 17;45(2):61-65. (PMID: 33709890)
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S54-S62. (PMID: 30895215)
Rev Chil Pediatr. 2020 Aug;91(4):553-560. (PMID: 33399732)
Medicina (B Aires). 2022;82(5):722-731. (PMID: 36220029)
Antimicrob Resist Infect Control. 2024 Nov 3;13(1):132. (PMID: 39491033)
Rev Assoc Med Bras (1992). 2024 May 20;70(5):e20231282. (PMID: 38775503)
Antimicrob Steward Healthc Epidemiol. 2022 Apr 22;2(1):e68. (PMID: 36483374)
Clin Infect Dis. 2021 Dec 1;73(Suppl_4):S258-S266. (PMID: 34850836)
Medicina (B Aires). 2022;82(5):641-646. (PMID: 36220019)
JAC Antimicrob Resist. 2021 Jul 16;3(3):dlab092. (PMID: 34286272)
Rev Panam Salud Publica. 2020 Sep 23;44:e57. (PMID: 32973905)
Cad Saude Publica. 2022 Aug 10;38(7):e00168021. (PMID: 35976345)
Antimicrob Steward Healthc Epidemiol. 2023 Sep 26;3(1):e162. (PMID: 37771737)
Braz J Infect Dis. 2021 Mar-Apr;25(2):101560. (PMID: 33716018)
Antibiotics (Basel). 2023 Mar 24;12(4):. (PMID: 37107010)
Rev Chilena Infectol. 2021 Jun;38(3):317-323. (PMID: 34479286)
Rev Bras Ter Intensiva. 2022 Oct-Dec;34(4):418-425. (PMID: 36888821)
Rev Chilena Infectol. 2021 Aug;38(4):480-487. (PMID: 34652392)

ID: 300008 International Centre for Antimicrobial Resistance Solutions (ICARS)

Keywords: AMR; Bacterial; Drug resistance; Latin America; One health; Program evaluation; Review literature as topic

0 (Anti-Bacterial Agents)

Date Created: 20251111 Date Completed: 20251112 Latest Revision: 20251210

20251210

PMC12607118

10.1186/s13756-025-01629-z

41220030